Virginia G. Kaklamani, MD, DSc

Articles

HR+ Metastatic Breast Cancer: Molecular Profiling and 1L Treatment Approaches

February 23rd 2023

Shifting their focus to HR+ metastatic disease, expert panelists consider the importance of molecular profiling and first-line treatment options.

Dr. Kaklamani on Racial Disparities and Clinical Outcomes in the RxPONDER Trial in Breast Cancer

February 22nd 2023

Virginia Kaklamani, MD, discusses how racial disparities may affect patient outcomes and treatment expectations based on data from the RxPONDER trial in breast cancer.

Expert Perspectives on Defining HER2-Low Breast Cancer

February 21st 2023

Centered discussion on the advent of HER2-low breast cancer and how it is differentiated from HER2+ and HER2- disease.

Overview on Treatment Options for HER2+ Breast Cancer

February 21st 2023

Expert panelists provide a broad overview on HER2+ breast cancer and review the evolving treatment armamentarium.

How Clinical Trials Inform Treatment Selection in Early-Stage HR+ Breast Cancer

February 16th 2023

A brief review of prevalent clinical trials in the early-stage HR+ breast cancer paradigm and how they help to inform treatment decision-making.

Early-Stage HR+ Breast Cancer: Ki67 and the monarchE Trial

February 16th 2023

Key opinion leaders in breast cancer management discuss Ki67 and the monarchE trial, which analyzed abemaciclib therapy in the HR+ space.

How Ki67 Informs Use of Therapy in Early-Stage HR+ Breast Cancer

February 9th 2023

A broad look at the role of Ki67 expression in informing the selection of therapy for patients with early-stage HR+ breast cancer.

Best Practices for Molecular Testing in Early-Stage Breast Cancer

February 9th 2023

Expert panelists share their perspectives on best practices for molecular profiling in patients diagnosed with early-stage breast cancer.

EMERALD Phase 3 Trial of Elacestrant Versus Standard of Care Endocrine Therapy in Patients With ER+/HER2- Metastatic Breast Cancer: Updated Results by Duration of Prior CDK4/6i in Metastatic Setting

December 22nd 2022

Virginia Kaklamani, MD reviews updated results and clinical implications of the phase 3 EMERALD trial evaluating elacestrant in patients with ER+/HER2- metastatic breast cancer presented at the 2022 San Antonio Breast Cancer Symposium.

Dr. Kaklamani on the Evolution of Oral SERDs in ER+ Breast Cancer

December 19th 2022

Virginia G. Kaklamani, MD, discusses the evolution of oral selective estrogen receptor degraders in estrogen receptor-positive breast cancer.

Dr. Kaklamani on the Use of Adjuvant Olaparib in Germline BRCA1/2-Mutant Breast Cancer

September 2nd 2022

Virginia G. Kaklamani, MD, discusses the use of adjuvant olaparib in germline BRCA1/2-mutant breast cancer.

SABCS 2021: Novel Approaches to Breast Cancer Management

January 24th 2022

After discussing a few more key datasets from the SABCS 2021 Virtual Meeting, expert panelists discuss how they would approach treatment in several subsets of breast cancer.

SABCS 2021: Brain Metastases Updates in Breast Cancer

January 24th 2022

Focusing on datasets from the SABCS 2021 Virtual Meeting, panelists consider novel approaches to the management of brain metastases in breast cancer.

SABCS 2021: Updates in Metastatic Breast Cancer

January 24th 2022

Expert panelists share their perspectives on metastatic breast cancer management datasets from the SABCS 2021 Virtual Meeting.

Coming Soon, HER2-Positive Breast Cancer: A Review of Data from the SABCS 2021 Virtual Meeting

December 23rd 2021

Virginia Kaklamani, MD, DSc, shares her excitement for an upcoming OncLive® "The TALK" program focusing on HER2-positive breast cancer updates from the SABCS 2021 Virtual Meeting.

T-DXd Versus T-DM1 in HER2+ MBC: Results of DESTINY-Breast03

October 28th 2021

Virginia Kaklamani, MD, DSc, presents results of the DESTINY-Breast03 clinical trial of trastuzumab deruxtecan compared with trastuzumab emtansine as treatment for patients with HER2-positive metastatic breast cancer.